TAP2 and neoplasm: These effects are associated with marked upregulation of SOCS1, a well-established inhibitor of the IFNγ/STAT proinflammatory pathway involved in multiple human diseases [33, 43], and could explain lower adaptive anti-tumor responses and reduced CD8+ TILs in TAP2-deficient NSCLCs.